At the news
? NEUTRALIMPACT 3/10 S-3 filed Apr 3, 2026 at 16:30 ET
Relmada Therapeutics filed an S-3 shelf registration to register the resale of 33,685,096 shares of common stock by selling stockholders, including 29,474,569 shares and 4,210,527 shares issuable upon exercise of pre-funded warrants, from a recent $160 million PIPE financing. The company will not receive proceeds from the resale, but the registration supports future capital raising flexibility. This follows strong clinical data for NDV-01 and a robust cash position extending into 2029.
- S-3 shelf registration filed for resale of 33,685,096 shares by selling stockholders from a March 2026 PIPE financing
- Offering includes 29,474,569 shares of common stock and 4,210,527 shares issuable upon exercise of pre-funded warrants
- Total offering value registered is $215.9 million based on a $6.41 share price
- Company will not receive any proceeds from the resale of shares by selling stockholders
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access